Guidant files suit against J&J to complete merger

Share this article:
Guidant filed a federal lawsuit yesterday to force Johnson & Johnson to complete its $25.4 billion acquisition of the company, The New York Times reports.
J&J contends the deal is now void because of Guidant's financial and legal problems.
Guidant, based in Indianapolis, disclosed yesterday that the Securities and Exchange Commission has opened a formal investigation into the timing of company disclosures about problem heart devices and trading in company stock. The company is already under investigation by the FDA and the Justice Department in connection with its handling of product safety issues.
The merger agreement, unless salvaged, would be one of the biggest ever to collapse because an acquiring company maintained that its target's value had fallen materially before the deal closed, the assertion J&J has made and Guidant has rejected, The Times reported.
In a statement, J&J said it planned on fighting Guidant's lawsuit, filed in U.S. District Court in Manhattan.
J&J has taken the position that Guidant's problems have affected its long-term outlook. Guidant has described any affect as short term.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.